World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
47278
World Ranking
10276
National Ranking
5282

Overview

Elizabeth M. Swisher is affiliated with the University of Washington in the United States. Their research primarily focuses on oncology, reproductive medicine, molecular biology, genetics, and cancer research, with a significant emphasis on ovarian cancer diagnosis and treatment as well as PARP inhibition in cancer therapy.

The scientist has contributed extensively to several main fields of study, including:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

The subfields in which Elizabeth M. Swisher has worked consist of:

  • Oncology
  • Reproductive Medicine
  • Molecular Biology
  • Genetics
  • Cancer Research

Research topics frequently addressed in their publication record include:

  • Ovarian cancer diagnosis and treatment
  • PARP inhibition in cancer therapy
  • BRCA gene mutations in cancer
  • Cancer Genomics and Diagnostics
  • DNA Repair Mechanisms
  • CRISPR and Genetic Engineering
  • Toxin Mechanisms and Immunotoxins

Elizabeth M. Swisher has published in a variety of scientific journals, with frequent contributions to the following venues:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature Communications

Their recent papers include:

  • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer (2020, Annals of Oncology)
  • Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020, Nature Communications)
  • An expanded universe of cancer targets (2021, Cell)
  • Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study (2020, Clinical Cancer Research)
  • Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) (2021, Nature Communications)

Frequent collaborators in their research include:

  • Marc R. Radke
  • Barbara M. Norquist
  • Robert L. Coleman
  • Enna Manhardt
  • Carol Aghajanian

Best Publications

  • Oncogenic Signaling Pathways in The Cancer Genome Atlas

    Francisco Sanchez-Vega;Marco Mina;Joshua Armenia;Walid K. Chatila

  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

    Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

  • Comprehensive Characterization of Cancer Driver Genes and Mutations.

    Matthew H Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Secondary mutations as a mechanism of cisplatin resistance in BRCA2 -mutated cancers

    Wataru Sakai;Elizabeth M. Swisher;Beth Y. Karlan;Mukesh K. Agarwal

  • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    Elizabeth M Swisher;Kevin K Lin;Amit M Oza;Clare L Scott

  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy

    Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

  • Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

    Tom Walsh;Silvia Casadei;Ming K. Lee;Christopher C. Pennil

  • Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

    Kathryn P. Pennington;Tom Walsh;Maria I. Harrell;Ming K. Lee

  • Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.

    André Kahles;Kjong-Van Lehmann;Nora C Toussaint;Matthias Hüser

  • Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

    Tom Walsh;Silvia Casadei;Kathryn Hale Coats;Elizabeth Swisher

  • Pathogenic Germline Variants in 10,389 Adult Cancers

    Kuan-Lin Huang;R Jay Mashl;Yige Wu;Deborah I Ritter

  • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    Robert L. Coleman;Gini F. Fleming;Mark F. Brady;Elizabeth M. Swisher

  • Inherited Mutations in Women With Ovarian Carcinoma

    Barbara M. Norquist;Maria I. Harrell;Mark F. Brady;Tom Walsh

  • Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

    Barbara Norquist;Kaitlyn A. Wurz;Christopher C. Pennil;Rochelle Garcia

  • Cowden Syndrome and the PTEN Hamartoma Tumor Syndrome: Systematic Review and Revised Diagnostic Criteria

    Robert Pilarski;Randall Burt;Wendy Kohlman;Lana Pho

  • NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.

    Mary B. Daly;Robert Pilarski;Michael Berry;Saundra S. Buys

  • Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing

    Tom Walsh;Ming K. Lee;Silvia Casadei;Anne M. Thornton

  • Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance

    Elizabeth M. Swisher;Wataru Sakai;Beth Y. Karlan;Kaitlyn Wurz

  • Genetic/familial high-risk assessment: breast and ovarian.

    Mary B. Daly;Jennifer E. Axilbund;Saundra Buys;Beth Crawford

Frequent Co-Authors

Clare L. Scott
Clare L. Scott Walter and Eliza Hall Institute of Medical Research
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
David M. O'Malley
David M. O'Malley The Ohio State University
Iain A. McNeish
Iain A. McNeish Imperial College London
Barbara A. Goff
Barbara A. Goff University of Washington
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Ming K. Lee
Ming K. Lee University of Washington
Mary Claire King
Mary Claire King University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical studies in the USA opens a variety of flexible online options for students seeking healthcare careers. For those interested in administrative work, understanding how much is medical billing and coding school can help you discover cost-effective pathways into the rapidly growing field of medical billing and coding.

If direct patient care is your goal, online nursing programs can be a smart starting point. Learn how much does online nursing school cost to make informed decisions about your investment and educational journey.

Advancing your career is possible through specialized options such as online nurse practitioner programs, which prepare you for greater responsibility and higher earning potential in clinical settings.

For those aiming for leadership roles in nursing, affordable doctoral pathways are achievable—consider learning about the cheapest dnp programs to maximize your educational value. Each of these online degrees supports a unique career path in the diverse and rewarding healthcare sector.

Best Scientists Citing Elizabeth M. Swisher

Trending Scientists

Recently Published Articles